Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
- J. Barrett, S. Hansoul, M. Daly
- BiologyNature Genetics
- 1 August 2008
The results strongly confirm 11 previously reported loci and provide genome-wide significant evidence for 21 additional loci, including the regions containing STAT3, JAK2, ICOSLG, CDKAL1 and ITLN1, which offer promise for informed therapeutic development.
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
- A. Franke, D. McGovern, M. Parkes
- BiologyNature Genetics
- 1 December 2010
A meta-analysis of six Crohn's disease genome-wide association studies and a series of in silico analyses highlighted particular genes within these loci implicated functionally interesting candidate genes including SMAD3, ERAP2, IL10, IL2RA, TYK2, FUT2, DNMT3A, DENND1B, BACH2 and TAGAP.
Infliximab for induction and maintenance therapy for ulcerative colitis.
- P. Rutgeerts, W. Sandborn, J. Colombel
- MedicineNew England Journal of Medicine
- 8 December 2005
Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Infliximab, azathioprine, or combination therapy for Crohn's disease.
- J. Colombel, W. Sandborn, P. Rutgeerts
- MedicineNew England Journal of Medicine
- 15 April 2010
Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or inflIXimab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azATHioprine monotherapy.
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.
- M. Daperno, G. D'Haens, P. Rutgeerts
- MedicineGastrointestinal Endoscopy
- 1 October 2004
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
- F. Baert, M. Noman, P. Rutgeerts
- Medicine, BiologyNew England Journal of Medicine
- 13 February 2003
The development of antibodies against infliximab is associated with an increased risk of infusion reactions and a reduced duration of response to treatment, and concomitant immunosuppressive therapy reduces the magnitude of the immunogenic response.
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
- B. Feagan, P. Rutgeerts, A. Parikh
- MedicineNew England Journal of Medicine
- 21 August 2013
Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis and the frequency of adverse events was similar in the vedolIZumab and placebo groups.
Infliximab maintenance therapy for fistulizing Crohn's disease.
- B. Sands, F. Anderson, S. V. van Deventer
- MedicineNew England Journal of Medicine
- 26 February 2004
Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
- J. Colombel, W. Sandborn, P. Pollack
- Medicine, BiologyGastroenterology
- 2007
Adalimumab was well-tolerated, with a safety profile consistent with previous experience with the drug, and was significantly more effective than placebo in maintaining remission in moderate to severe CD through 56 weeks.
...
...